Actively Recruiting
Tampere Coronary Artery Disease and Sudden Cardiac Arrest Study
Led by Tampere Heart Hospital · Updated on 2025-02-03
4000
Participants Needed
1
Research Sites
937 weeks
Total Duration
On this page
Sponsors
T
Tampere Heart Hospital
Lead Sponsor
T
Tampere University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to recognize clinical and genetic risk factors for sudden cardiac arrest (SCA) and death (SCD) in patients with coronary artery disease (CAD). The main questions it aims to answer are: Are we able to recognize clinical or treatment-related risk factors for SCA or SCD? Can we identify new genetic risk factors for SCA or SCD in patients under 75 years? Participants diagnosed with CAD answer a short survey about their medical history and socioeconomic status. A standard ECG addition to a five (5) minute ECG recording is taken from all the study subjects. In addition to a few short physiological tests (e.g. blood pressure, height, weight, grip strength), a blood sample is withdrawn from a selected group of study subjects. Medical healthcare records are used to follow all study subjects, and no follow-up visits are required.
CONDITIONS
Official Title
Tampere Coronary Artery Disease and Sudden Cardiac Arrest Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 18 years
- Living in the Wellbeing Services County of Pirkanmaa area and seeking treatment for coronary artery disease (CAD)
- CAD diagnosis confirmed by invasive coronary angiogram or computed tomography angiogram (CTA) evaluated by cardiologists
- Coronary angiogram or CTA performed within the last 3 months
- Good or moderate everyday functional ability
You will not qualify if you...
- Life expectancy less than 1 month
- Significant valvular heart disease treated previously or requiring treatment within the next 3 months
- Previously implanted cardioverter-defibrillators (ICD) or planned implantation within the next 3 months
- Active malignancy including ongoing treatment for solid or metastatic tumors or fast progressing hematological malignancy
- Significant neurodegenerative disease affecting everyday function (e.g. dementia with MMSE <23, ALS, myositis, progressive MS, Parkinson's disease)
- Intellectual disability or significant cognitive impairment
- Do-not-resuscitate (DNR) treatment decision
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tampere University Hospital Tampere Heart Centre
Tampere, Pirkanmaa, Finland, 33100
Actively Recruiting
Research Team
J
Jussi Hernesniemi, Professor
CONTACT
J
Juho Tynkkynen, Medical Doctor, Phd
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here